Evidence map›Paper›PMID 31598113›Full record

ArticleContrast media & molecular imaging2019

T2

Yukari Matsuo-Tezuka, Yusuke Sasaki, Toshiki Iwai, Mitsue Kurasawa, Keigo Yorozu, Yoshihito Tashiro, Michinori Hirata

Open access · hybridAbstract read
In one paragraph

Article in Contrast media & molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yukari Matsuo-TezukaProduct Research Department, Chugai Pharmaceutical Co. Ltd., Kamakura, Japan.
Yusuke SasakiProduct Research Department, Chugai Pharmaceutical Co. Ltd., Kamakura, Japan.
Toshiki IwaiProduct Research Department, Chugai Pharmaceutical Co. Ltd., Kamakura, Japan.
Mitsue KurasawaProduct Research Department, Chugai Pharmaceutical Co. Ltd., Kamakura, Japan.
Keigo YorozuProduct Research Department, Chugai Pharmaceutical Co. Ltd., Kamakura, Japan.
Yoshihito TashiroProduct Research Department, Chugai Pharmaceutical Co. Ltd., Kamakura, Japan.ORCID 0000-0002-3350-2432
Michinori HirataProduct Research Department, Chugai Pharmaceutical Co. Ltd., Kamakura, Japan.ORCID 0000-0001-7367-4012

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Iron overload is a life-threatening disorder that can increase the risks of cancer, cardiovascular disease, and liver cirrhosis. There is also a risk of iron overload in patients with chronic kidney disease. In patients with renal failure, iron storage is increased due to inadequate iron utilization associated with decreased erythropoiesis and also to the inflammatory status. To evade the risk of iron overload, an accurate and versatile indicator of body iron storage in patients with iron overload is needed. In this study, we aimed to find useful iron-related parameters that could accurately reflect body iron storage in mice in order to construct a murine model of iron overload. Methods: To select an appropriate indicator of body iron status, a variety of parameters involved in iron metabolism were evaluated. Noninvasively measured parameters were R1, R2, and R2 Results/Conclusion: Among the several parameters evaluated, the MRI T2

Indexed as

AnimalsDisease Models, AnimalFerritinsHemoglobinsHemosiderinHepcidinsInjections, IntraperitonealIronIron-Dextran ComplexIron OverloadLiverMagnetic Resonance ImagingMaleMiceMice, Inbred C57BLSpecific Pathogen-Free OrganismsFerritinsHamp protein, mouseHemoglobinsHemosiderinHepcidinsIronIron-Dextran Complex

Identifiers

PMID31598113
PMCPMC6778918
OpenAlexW2973589119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.